BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Next Safety, Inc. Breakthrough in Pulmonary Drug Delivery will Bring Numerous In-Hospital Treatments to the Home


12/19/2007 11:23:04 AM

JEFFERSON, N.C., Dec. 19 /PRNewswire/ -- Next Safety, Inc., a leader in developing pulmonary drug delivery devices, today announced verification of a significant breakthrough in pulmonary science that provides high efficacy delivery of drugs to the lungs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070615/CLF038LOGO )

Advanced optical characterization techniques performed by a third party laboratory showed that 99.8% of the droplets delivered by Next Safety's pulmonary drug delivery devices were between one and three microns in diameter, and the droplets separated sufficiently in space and time to be absorbed into the alveoli of the lungs.

The company has already demonstrated more rapid delivery of nicotine to the bloodstream through the lungs than possible with cigarettes.

Four of the ten largest global pharmaceutical companies have expressed interest in the company's pulmonary business. Next Safety expects to begin a bidding process for its pulmonary business in early 2008.

Next Safety's immediate and ongoing research studies focus on the pulmonary delivery of nicotine, albuterol, tobramyacin and long chain peptide and protein molecules. Nicotine delivery and other clinical findings from brain imaging and arterial blood studies conducted in partnership with a major U.S. medical institution will be announced in the first quarter of 2008.

"Previous nicotine replacement products have helped millions of smokers worldwide. However the delivery mechanisms of these products cannot equal the power of nicotine delivered through the smoked cigarette. The next step in nicotine replacement treatment is the ability to deliver nicotine directly to the lung and brain, in the same manner as a cigarette, without the 4,000 harmful chemicals in tobacco" said Matthew Bars, MS, CTTS, an expert in nicotine addiction, key opinion leader and consultant to the pharmaceutical industry and Next Safety, Inc. Mr. Bars is the Director of the New York City Fire Department's Tobacco Cessation Program. "Pulmonary delivery of 'clean' nicotine would become the gold standard of nicotine replacement therapies. The Next Safety pulmonary nicotine delivery device has the potential of saving the lives of hundreds of millions of smokers worldwide" Bars concluded.

For more information about Next Safety, Inc. or the bidding process, please visit our website www.nextsafety.com.



CONTACT: Christy Cheek of Next Safety, Inc., +1-336-246-7700,
christycheek@nextsafety.com

Web site: http://www.nextsafety.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES